MAPT and Alzheimer disease: While therapeutic agents targeting the two main pathologies, extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles, are in development, and three anti-amyloid antibodies have either been given FDA approval (aducanamab, lecanamab) or will be submitted for approval soon (donanemab), there is still a need to understand the risk factors for AD and their contribution to disease etiology.